CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Hepatic ImpairmentBusiness Wire • 09/19/23
Kite's Car T-cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients With Relapsed/Refractory Large B-cell LymphomaBusiness Wire • 09/18/23
Gilead Sciences, Inc. (GILD) Management Presents at Morgan Stanley 21st Annual Global Healthcare Brokers Conference 2023 (Transcript)Seeking Alpha • 09/12/23
Big Institutions Grab ‘Strong Buy' Dividend Stocks in a Sector Not Totally Driven by AI24/7 Wall Street • 09/11/23
Gilead's Phase 2 EVOKE-02 Study of Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) Demonstrates Promising Clinical Activity in First-Line Metastatic Non-Small Cell Lung CancerBusiness Wire • 09/10/23
The Unexpected Reason Gilead Just Notched Its Biggest Single-Day Move In A MonthInvestors Business Daily • 09/08/23
Gilead Sciences, Inc. (GILD) Wells Fargo Healthcare Conference - (Transcript)Seeking Alpha • 09/06/23
GILD Stock Alert: FDA Expands Indications for Gilead Sciences' Veklury Covid-19 TreatmentInvestorPlace • 08/24/23
FDA Approves Veklury® (Remdesivir) to Treat COVID-19 in People With Mild to Severe Hepatic Impairment With no Dose AdjustmentBusiness Wire • 08/24/23
Cancer drug stocks soar after Roche accidentally releases positive interim lung cancer trial resultsProactive Investors • 08/23/23
Gilead, Arcus, iTeos, other biopharmas get boost from accidental disclosure of Roche lung cancer trial dataMarket Watch • 08/23/23
Gilead Sciences told by FDA to pause patient enrollment in leukemia drug trialsProactive Investors • 08/21/23